Cellectis (CLLS) Revenue Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 122.97% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 7.94% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 4.47% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 54.05% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 246.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 246.39% |
| Dec 31, 2025 | -7.42% |
| Sep 30, 2025 | 485.76% |
| Jun 30, 2025 | 133.90% |
| Mar 31, 2025 | 85.66% |
| Dec 31, 2024 | 25.80% |
| Sep 30, 2024 | 24.91% |
| Jun 30, 2024 | -10.32% |
| Mar 31, 2024 | -43.87% |
| Dec 31, 2023 | -72.53% |
| Sep 30, 2023 | -70.73% |
| Jun 30, 2023 | -60.55% |
| Mar 31, 2023 | -85.95% |
| Dec 31, 2022 | 53.59% |
| Sep 30, 2022 | -72.58% |
| Jun 30, 2022 | 4.30% |
| Mar 31, 2022 | 17.13% |
| Dec 31, 2021 | 119.68% |
| Sep 30, 2021 | 109.34% |
| Jun 30, 2021 | 30.32% |
| Mar 31, 2021 | 61.84% |
| Dec 31, 2020 | 25.47% |
| Sep 30, 2020 | 0.31% |
| Jun 30, 2020 | -23.56% |
| Mar 31, 2020 | 95.22% |
| Dec 31, 2019 | -18.59% |
| Sep 30, 2019 | -9.01% |
| Jun 30, 2019 | 19.53% |
| Mar 31, 2019 | -48.75% |
| Dec 31, 2018 | -70.10% |
| Sep 30, 2018 | -52.50% |
| Jun 30, 2018 | -14.57% |
| Mar 31, 2018 | -14.08% |